The FDA cleared Merck’s Idvynso (doravirine/islatravir), giving providers a new once-daily option for adults with HIV-1 who are already virologically suppressed and have no history of treatment failure, along with specified resistance constraints. The approval arrives ahead of the drug’s April 28 PDUFA date, according to reporting. Idvynso is a two-drug regimen designed to pair mechanisms that suppress HIV replication, with dosing positioned to expand choice for patients needing alternatives due to safety or tolerability. The authorization also brings renewed competitive pressure on established regimens such as Gilead’s Biktarvy. For biotech and pharma, the decision underscores continuing movement toward simpler regimens and incremental innovation within the suppressed-patient population. It also provides a concrete regulatory milestone for Merck’s effort to reassert presence in HIV after years of competitive repositioning. Clinically, the label reflects a narrower switch use case than de novo initiation strategies, but it still matters for sequencing of therapy when patients require changes rather than first-line starts.